米氮平作为非小细胞肺癌伴厌食患者的食欲刺激剂:一项随机临床试验
这项随机双盲安慰剂对照试验在晚期非小细胞肺癌伴厌食成人患者中评估米氮平对食欲和能量摄入的影响,共随机86例(米氮平组43例、安慰剂组43例),随访8周。结果显示两组食欲评分无差异,但米氮平组在4周和8周随访期间能量摄入显著增加,主要为脂肪摄入增加,且8周时肌肉减少症患者比例显著降低。
要点
- 米氮平组与安慰剂组在4周和8周时食欲评分无差异。
- 米氮平组4周时能量摄入显著增加379.3 kcal(95%CI 1382.6-576.1,P<.001)。
- 米氮平组8周时肌肉减少症患者比例显著降低(82.8% vs 57.1%,P=.03)。
核心结论
- 在晚期非小细胞肺癌患者中,米氮平组与安慰剂组食欲评分无差异,但米氮平组在4周和8周随访期间能量摄入显著增加,主要为脂肪摄入增加。
- 作者认为,在晚期非小细胞肺癌伴厌食患者中加入米氮平可能帮助患者达到能量需求并改善健康相关生活质量,特别是情绪和认知功能。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,2018年8月至2022年5月在一家三级癌症中心进行,随访8周。
- 共筛查134例患者,114例评估合格,排除28例;86例符合纳入标准并随机分组,安慰剂组43例、米氮平组43例。
- 干预为米氮平15 mg或安慰剂1:1随机,2周后剂量递增至30 mg至第8周或安慰剂;两组均接受营养评估和饮食建议。
主要发现
- 两组在4周和8周后食欲评分无差异。
- 4周后米氮平组能量摄入显著增加379.3 kcal(95%CI 1382.6-576.1,P<.001),包括蛋白质22.5 g(95%CI 11.5-33.4,P=.001)、碳水化合物43.4 g(95%CI 13.1-73.8,P=.006)和脂肪13.2 g(95%CI 6.0-20.4,P=.006)。
- 8周后米氮平组脂肪摄入显著高于安慰剂组(14.5 g vs 0.7 g,P=.02)。
- 8周时米氮平组肌肉减少症患者比例显著降低(82.8% vs 57.1%,P=.03)。
- 米氮平组治疗耐受良好,但2周时基于10 cm VAS评分的噩梦感知高于对照组(0 [25th-75th百分位,0-1] vs 0 [25th-75th百分位,0-0],P=.009),4周和8周时该差异无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Currently there is no standard therapy to improve cancer-related anorexia, hampering survival. Mirtazapine has been suggested as a feasible option in this context. OBJECTIVES: To assess the effect of mirtazapine on appetite and energy consumption in patients with advanced non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled clinical trial including adults was performed in a tertiary cancer care center from August 2018 to May 2022 with a follow-up of 8 weeks. Overall, 134 patients were screened; 114 were assessed for eligibility and 28 were excluded. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive mirtazapine, 15 mg, or placebo for 2 weeks followed by a dose escalation to 30 mg until week 8 or placebo. Both groups received nutritional assessment and dietary advice. MAIN OUTCOMES AND MEASURES: Appetite was assessed by the Anorexia Cachexia Scale and energy intake. Dietary parameters were evaluated at baseline, 4 weeks, and 8 weeks, with a 24-hour dietary recall, and energy quantification based on the Mexican system of nutritional equivalents. RESULTS: A total of 86 patients met the inclusion criteria and were randomized to the placebo (n = 43) or the mirtazapine group (n = 43). The mean (SD) age was 63.5 (11.2) years, 41 were women (57.7%) and had adenocarcinoma, Eastern Cooperative Oncology Group performance status scale score of 1, stage IV NSCLC, and were receiving first-line treatment. Baseline characteristics were similar between groups. There was no difference in appetite scores in patients who received mirtazapine or placebo after 4 and 8 weeks. After 4 weeks, mirtazapine significantly increased energy intake (379.3 kcal; 95% CI, 1382.6-576.1; P < .001) including proteins (22.5 g; 95% CI, 11.5-33.4; P = .001), carbohydrates (43.4 g; 95% CI, 13.1-73.8; P = .006), and fats (13.2 g; 95% CI, 6.0-20.4; P = .006). Fats intake was significantly higher in patients in the mirtazapine group (14.5 g vs 0.7 g; P = .02) after 8 weeks. The mirtazapine group significantly decreased the proportion of patients with sarcopenia (82.8% vs 57.1%, P = .03) at 8 weeks. Patients on mirtazapine tolerated the treatment well, but reported a higher perception of nightmares at 2 weeks based on a 10 cm VAS score (0 [25th-75th percentile, 0-1] vs 0 [25th-75th percentile, 0-0] in the control group; P = .009) but this finding was nonsignificant after 4 and 8 weeks. CONCLUSION AND RELEVANCE: In this randomized clinical trial of patients with advanced NSCLC, there was no difference in appetite scores in all patients who received mirtazapine or placebo, but the mirtazapine group had a significant increase in energy intake through the 4- and 8-week follow-up, mainly in fat intake, which is a better and crucial source of energy. The addition of mirtazapine in the treatment of patients with advanced NSCLC and anorexia may help these patients achieve their energy requirements and improve health-related quality of life, specifically emotional and cognitive functioning. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04748523.
引用
- Arrieta O, Cárdenas-Fernández D, Rodriguez-Mayoral O, et al. Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38206631. doi:10.1001/jamaoncol.2023.5232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。